Testing a new every-2-week pill for type 2 diabetes
Part of Hormones & metabolism clinical trials.
This study tests a new once-every-2-weeks pill (cofrogliptin) added to your current diabetes medications (metformin and dapagliflozin) compared to a daily pill (linagliptin). It may help improve blood sugar control with fewer daily pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have type 2 diabetes and are currently taking both metformin (at least 1000 mg per day) and dapagliflozin (10 mg daily) for at least 12 weeks.
- Your A1C (average blood sugar over 3 months) is between 7.0% and 10.0%.
- Your fasting blood sugar is below 15 mmol/L.
- You have no serious kidney, liver, or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new GLP-1 receptor agonist to improve blood sugar control in people with type 2 diabetes. It may be an option if you haven't used a similar drug in the last three months and your medical records are complete.
This study tests a new pill called HDM1002 for adults with type 2 diabetes. It aims to see if it helps control blood sugar when added to your current metformin treatment.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
This trial tests if adding either cofrogliptin or linagliptin (two pills that help control blood sugar) to your current insulin treatment can improve diabetes control. It is for adults with type 2 diabetes whose blood sugar is still not well managed with insulin and certain other diabetes pills.
This study tests if a new medicine (elecoglipron) combined with dapagliflozin is safe and works better for adults with type 2 diabetes that isn't well controlled by diet or other medications.
This trial tests a new combination pill (henagliflozin and metformin) compared to metformin alone in people recently diagnosed with type 2 diabetes. The goal is to see which treatment works better and is safer.
Hear when a new T2DM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.